Your binder contains too many pages, the maximum is 40.
We are unable to add this page to your binder, please try again later.
This page has been added to your binder.
June 27, 2005
LONDON, UK, June 27, 2005 - Covington & Burling, in association with financial intelligence company mergermarket, released the Covington Life Sciences Monitor. The report, the result of a survey of senior life sciences corporate executives and investment bankers in the U.S. and Europe, gauges perceptions and expectations for the sector.
The Monitor focuses on M&A expectations, U.S. and European market considerations, and research and development within the life science industry. The report also contains a special report on the biotech sector.
"The need to fill drug pipelines will lead to further consolidation of the industry and to an increase in licensing, joint ventures and commercial partnering, especially between pharma and biotech companies," says Peter Bogaert, Covington life sciences partner. "These developments are a result of the need to protect and maintain an innovative and competitive life sciences industry.